Subodh Selukar

Subodh Selukar

Auto-generated profile, based on publicly available information

Subodh Selukar

Department of Biostatistics St. Jude Children's Research Hospital Memphis Tennessee USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
TGTerry B. Gernsheimer
Terry B. Gernsheimer
SBSiobhan P. Brown
Siobhan P. Brown
DTDarrell J. Triulzi
Darrell J. Triulzi
NKNigel S. Key
Nigel S. Key
NKNahed El Kassar
Nahed El Kassar
SMSusanne May
Susanne May
Evidence of the effectiveness of prophylactic use of tranexamic acid (TXA) in thrombocytopenia is lacking. To determine whether TXA safely reduces bleeding incidence in patients undergoing treatment for hematologic malignancies, a randomized, double-blind clinical trial was conducted from June 2016 through June 2020. Of 3120 screened adults, 356 patients were eligible and enrolled, and 337 patients (mean age, 53.9; 141 [41.8%] women), randomized to 1300 mg TXA orally or 1000 mg TXA through IV (n = 168) vs placebo (n = 169) thrice daily for maximum 30 days. Three hundred thirty patients were activated when their platelet counts fell below 30 000 per µL; 279 (83%) had complete outcome ascertainment. World Health Organization (WHO) grade ≥2 bleeding was observed in the 30 days following activation in 50.3% (73/145) and 54.2% (78/144) of patients in the TXA and placebo groups, with an adjusted odds ratio of 0.83 (95% confidence interval [CI], 0.50-1.34; P = .44). There was no statistically significant difference in the mean number of platelet transfusions (mean difference, 0.1; 95% CI, −1.9 to 2.0), mean days alive without grade ≥2 bleeding (mean difference, 0.8; 95% CI, −0.4 to 2.0), thrombotic events (6/163 [3.7%] TXA, 9/163 [5.5%] placebo), or deaths due to serious bleeding. Most common adverse events were: diarrhea (116/164 [70.7%] TXA and 114/163 [69.9%] placebo); febrile neutropenia (111/164 [67.7%] TXA, 105/163 [64.4%] placebo); fatigue (106/164 [64.6%] TXA, 109/163 [66.9%] placebo); and nausea (104/164 [63.4%] TXA, 97/163 [59.5%] placebo). Among patients with hematologic malignancy undergoing chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment with TXA compared with placebo did not significantly reduce the risk of WHO grade ≥2 bleeding.

15 January 2025 in Blood Advances
Verified
Journal Article
Open access
DZDua’a Zandaki
Dua’a Zandaki
SSSubodh Selukar
Subodh Selukar
YBYu Bi
Yu Bi
YLYing Li
Ying Li
MZMegan Zinsky
Megan Zinsky
ACAimee C
Aimee C
Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are complications of CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy. The Endothelial Activation and Stress Index (EASIX) and modified EASIX (m-EASIX) scores have been retrospectively proven to be predictive of CRS and ICANS in adult CAR T-cell recipients. However, these scores have not been evaluated in pediatric cohorts. We retrospectively report on 76 pediatric and adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with CD19-CAR T cells at St. Jude Children’s Research Hospital or Johns Hopkins Hospital. Data included patient, disease, and treatment characteristics. EASIX and m-EASIX scores were calculated at days –5 before, 0, and +3 after CAR T-cell infusion. CRS and ICANS occurred in 47 and 17 patients, respectively. At all evaluated time points, the median EASIX scores were higher for patients who developed severe CRS and any grade ICANS, and the median m-EASIX scores were higher in patients who developed severe CRS and severe ICANS than those with no/mild CRS/ICANS. Receiver operating characteristic curve analysis showed that both scores were strong predictors of CRS, especially severe CRS, at all time points. Any grade and severe ICANS were best predicted by both scores at day +3. m-EASIX uniformly outperformed EASIX, except for predicting any grade ICANS. Our results validate the potential utility of EASIX and m-EASIX scores for predicting CAR T-cell–related complications for pediatric and AYA patients.

23 October 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
JSJaneth I. Sanchez
Janeth I. Sanchez
VSVeena Shankaran
Veena Shankaran
JUJoseph M. Unger
Joseph M. Unger
MMMargaret M. Madeleine
Margaret M. Madeleine
SSSubodh R. Selukar
Subodh R. Selukar
BTBeti Thompson
Beti Thompson

16 March 2023 in Blood
Verified
Journal Article
Closed access
PDF file
CMCara Morin
Cara Morin
ASAkshay Sharma
Akshay Sharma
SSSubodh Selukar
Subodh Selukar
Gary Scott BeasleyGary Scott Beasley
Gary Scott Beasley
AMAnthony Merlocco
Anthony Merlocco
Jason Nathaniel JohnsonJason Nathaniel Johnson
Jason Nathaniel Johnson
Cara Morin, Akshay Sharma, Subodh Selukar, Gary Beasley, Anthony Merlocco, Chris Goode, Parul Rai, Jeffrey Allen Towbin, Jane S Hankins, Jason Nathaniel Johnson

21 August 2021 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
SSSubodh Selukar
Subodh Selukar
SMSusanne May
Susanne May
DLDave Law
Dave Law
MOMegan Othus
Megan Othus
Background: Platform trials facilitate efficient use of resources by comparing multiple experimental agents to a common standard of care arm. They can accommodate a changing scientific paradigm within a single trial protocol by adding or dropping experimental arms—critical features for trials in rapidly developing disease areas such as COVID-19 or cancer therapeutics. However, in these trials, efficacy and safety issues may render certain participant subgroups ineligible to some experimental arms, and methods for stratified randomization do not readily apply to this setting. Methods: We propose extensions for conventional methods of stratified randomization for platform trials whose experimental arms may differ in eligibility criteria. These methods balance on a prespecified set of stratification variables observable prior to arm assignment that remains the same across experimental arms. To do so, we suggest modifying block randomization by including experimental arm eligibility as a stratifying variable, and we suggest modifying the imbalance score calculation in dynamic balancing by performing pairwise comparisons between each eligible experimental arm and standard of care arm participants eligible to that experimental arm. Results: We provide worked examples to illustrate the proposed extensions. In addition, we also provide a formula to quantify the relative efficiency loss of platform trials with varying eligibility compared with trials with non-varying eligibility as measured by the size of the common standard of care arm. Conclusions: This article presents important extensions to conventional methods for stratified randomization in order to facilitate the implementation of platform trials with differing experimental arm eligibility.

8 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
ASAkshay Sharma
Akshay Sharma
SSSubodh Selukar
Subodh Selukar
YBYu Bi
Yu Bi
AMAnthony Merlocco
Anthony Merlocco
CMCara Morin
Cara Morin
Jason Nathaniel JohnsonJason Nathaniel Johnson
Jason Nathaniel Johnson
Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.